Brand Names of Cinnarizine and Dimenhydrinate Fixed Combination
The fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg is marketed under the brand name Arlevert®. 1
Available Formulations
- Arlevert® is the proprietary name for the fixed-dose combination tablet containing cinnarizine 20 mg plus dimenhydrinate 40 mg 1
- This combination is specifically formulated for the treatment of vertigo and related vestibular disorders 1, 2
Clinical Context
- The fixed combination leverages complementary mechanisms: cinnarizine acts predominantly peripherally on the labyrinth through anti-vasoconstrictor activity and reduction of nystagmus, while dimenhydrinate acts centrally on vestibular nuclei and associated centers in the brainstem 2
- Standard dosing is one tablet three times daily for acute vestibular vertigo, with treatment durations typically ranging from 4 to 8 weeks 3, 1, 4
Evidence Supporting This Combination
- The fixed combination demonstrated superiority over betahistine 16 mg (the most widely prescribed anti-vertigo drug worldwide) in reducing mean vertigo scores after 4 weeks of therapy in a randomized, double-blind, non-inferiority trial involving 306 patients 1
- Clinical studies consistently show 61-95% improvement rates in vertigo symptoms, with excellent tolerability profiles showing only 3.7-3.9% adverse event rates 3, 1
- The combination is more effective than either cinnarizine or dimenhydrinate monotherapy, with significantly better symptom relief after just 1 week of treatment 4